

CRISPR/Cas9 – Market Players Snapshot

We're entering a new era in molecular biology.

A new tool based on a bacterial CRISPR-associated protein-9 nuclease (Cas9) from *Streptococcus pyogenes* will enable the development of efficient and reliable ways to make precise targeted changes to the genome of living cells.

The discovery however, is mired in a bitter patent war that has marred the biggest biotechnology advance since the polymerase chain reaction.

On the 11th of January, 2016, the USPTO approved a request to review a key patent pertaining to the CRISPR–Cas9 technique. This patent interference is estimated to be worth millions for the warring research institutions/ inventors.

Despite the ongoing patent war, a lot of startups and industry heavyweights have jumped on to the CRISPR/Cas9 bandwagon, seeing its potential in creating cures for various diseases such as AIDS, Cancer, and many more.

Here's a snapshot of the market players involved.

CRISPR/CAS9 MARKET SNAPSHOT



Note: The research collaboration between Astrazeneca and Broad institute involves more partners: Wellcome Trust Sanger Institute, Innovative Genomics Initiative, Thermo Fisher Scientific, and Whitehead Institute

- With millions of dollars invested in the technology, the patent war on CRISPR/Cas9 has fragmented the market into individual inventors/ universities based clusters.
- Horizon discovery group has licenses from all the three foundational patent inventors/ universities.
- Cocystal Pharma is the latest entrant in the domain with licensed technology from Duke and Emory universities in Feb 2016.

Compiled by: Peeyush Kavi

© 2016 Aranca. All Rights Reserved. www.aranca.com
If you wish to reproduce or use this infographic in any format, please email us at marketing@aranca.com



About Aranca:

Aranca is a leading provider of high quality, customized and cost effective research and analytics to global clients. Founded in UK in 2003, Aranca has a global presence including in the US, Europe and Middle East, and a state-of-the-art delivery center in Mumbai, India.

Our research solutions are structured around four complementary business lines: [Investment Research](#), [Business Research](#), [Valuation and Advisory Services](#) and [Intellectual Property Research](#).

Over the years, Aranca has become a trusted partner to over 1500 global organizations including Fortune 500 companies, SMBs, [investment banks](#), [brokerage firms](#), [asset management firms](#), [consulting firms](#), [PE and VC firms](#), [law firms](#), government bodies, trade associations and universities.